Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity sca
Atea Pharmaceuticals (AVIR) said Tuesday a pivotal phase 3 trial of its experimental combination the
As the biopharmaceutical industry prepares to convene for Cambridge Healthtech Institute's 18th Annual Bioprocessing Summit, taking place August 10-13, 2026, in Boston, this year's program will focus
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today provided an update on the development of opaganib1 for Ebola virus disease (EVD) as the
Atea Pharmaceuticals announced positive Phase 3 C-BEYOND trial results for its oral hepatitis C combination therapy vs. Gilead's therapy.
Kalshi sees drug development predictions as a way to improve R&D transparency. Critics say they could create financial incentives around research and undermine public trust.
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $166 to $165.
View interactive chart, options flow, and AI analysis for GILD on Zorveq Finance.
Open GILD Chart & Analysis →